DNA cross-links in human tumor cells exposed to the prodrug pr-104a:relationships to hypoxia, bioreductive metabolism, and cytotoxicity

Cancer Research

Volumn 69, Issue 9, 2009, Pages 3884-3891

  Singleton, Rachelle S ^a   Guise, Christopher P ^a   Ferry, Dianne M ^a   Pullen, Susan M ^a   Dorie, Mary J ^b   Brown, J Martin ^b   Patterson, Adam V ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; ANTINEOPLASTIC AGENT; HYDROXYLAMINE; PR 104A; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL KILLING; CLONOGENIC ASSAY; COMET ASSAY; CONTROLLED STUDY; DNA CROSS LINKING; DRUG CYTOTOXICITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYPOXIA; MASS SPECTROMETRY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; CELL DEATH; CELL HYPOXIA; CELL LINE, TUMOR; CHLORAMBUCIL; CHROMATOGRAPHY, LIQUID; DNA DAMAGE; DNA, NEOPLASM; FEMALE; HCT116 CELLS; HT29 CELLS; HUMANS; MICE; MICE, NUDE; NEOPLASMS; NITROGEN MUSTARD COMPOUNDS; PRODRUGS; TANDEM MASS SPECTROMETRY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 65949102556     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4023     Document Type: Article

References (47)

1. Bristow RG, Hill RP. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008; 8: 180-92.
2. Vaupel P, Mayer A. Hypoxia in cancer:significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26: 225-39.
3. Brown JM, Wilson WR. Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer 2004; 4: 437-47.
4. Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia:importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006; 82: 699-757.
5. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
6. McKeown SR, Cowen RL, Williams KJ. Bioreductive drugs:fromconcept to clinic. Clin Oncol 2007; 19: 427-42.
7. Ahn GO, Brown M. Targeting tumors with hypoxia-activated cytotoxins. Front Biosci 2007; 12: 3483-501.
8. Chen Y, Hu L. Design of anticancer prodrugs for reductive activation. Med Res Rev 2009; 29: 29-64.
9. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008; 8: 425-37.
10. Ader I, Brizuela L, Bouquerel P, Malavaud B, Cuvillier O. Sphingosine kinase 1:a new modulator of hypoxia inducible factor 1apha during hypoxia in human cancer cells. Cancer Res 2008; 68: 8635-42.
11. Aprelikova O, Pandolfi S, Tackett S, et al. Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response. Cancer Res 2009; 69: 616-24.
12. Wardman P. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr Med Chem 2001; 8: 739-61.
13. Rischin D, Peters L, O'Sullivan B, et al. Phase III study of tirapazamine, cisplatin and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck. ASCO Meeting Abstracts 2008: 6008.
14. Rischin D, Fisher R, Peters L, Corry J, Hicks R. Hypoxia in head and neck cancer:Studies with hypoxic positron emission tomography and hypoxic cytotoxins. Int J Radiat Oncol Biol Phys 2007; 69: S61-63.
15. Koukourakis MI, Bentzen SM, Giatromanolaki A, et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 a and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 2006; 24: 727-35.
16. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005; 77: 18-24.
17. Stadler P, Becker A, Feldmann HJ, et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1999; 44: 749-54.
18. Patterson AV, Ferry DM, Edmunds SJ, et al. Mechanismof action and preclinical antitumor activity of the novel hypoxia-activated DNA crosslinking agent PR-104. Clin Cancer Res 2007; 13: 3922-32.
19. Hicks KO, Myint H, Patterson AV, et al. Oxygen dependence and extravascular transport of hypoxiaactivated prodrugs:comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. Int J Radiat Oncol Biol Phys 2007; 69: 560-71.
20. Jameson MB, Rischin D, Pegram M, et al. A phase I pharmacokinetic study of PR-104, a hypoxia-targeting agent, in patients with solid tumors. J Clin Oncol 2007; 25: 3516.
21. Lee AE, Wilson WR. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol Appl Pharmacol 2000; 163: 50-9.
22. Parmar K, Mauch P, Vergilio J, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A 2007; 104: 5431-6.
23. Wilson WR, Hicks KO, Pullen SM, et al. Bystander effects of bioreductive drugs:potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. Radiat Res 2007; 167: 625-36.
24. Green SL, Giaccia AJ. Tumor hypoxia and the cell cycle:implications for malignant progression and response to therapy. Cancer J Sci Am 1998; 4: 218-23.
25. Kennedy AS, Raleigh JA, Perez GM, et al. Proliferation and hypoxia in human squamous cell carcinoma of the cervix:first report of combined immunohistochemical assays. Int J Radiat Oncol Biol Phys 1997; 37: 897-905.
26. Tannock IF. The relation between cell proliferation and the vascular systemin a transplanted mouse mammary tumour. Br J Cancer 1968; 22: 258-73.
27. Bergstralh DT, Sekelsky J. Interstrand crosslink repair:can XPF-ERCC1 be let off the hook? Trends Genet 2008; 24: 70-6.
28. Thompson LH, Hinz JM. Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair:mechanistic insights. Mutat Res-Fund Mol Mech Mutagen 2009; doi: 10.1016/j.mrfmmm.2009.02.003.
29. Osborne MR, Lawley PD, Croftonsleigh C, Warren W. Products fromalkylation of DNA in cells by melphalan:human soft tissue sarcoma cell line RD and Escherichia coli WP2. Chem-Biol Interact 1995; 97: 287-96.
30. Souliotis VL, Dimopoulos MA, Sfikakis PP. Genespecific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards. Clin Cancer Res 2003; 9: 4465-74.
31. Bruce WR, Meeker BE, Valeriote FA. Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 1966; 37: 233-45.
32. Pruijn FB, van Daalen M, Holford NH, Wilson WR. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5, 6- dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1997; 39: 541-6.
33. Denny WA, Wilson WR. Bioreducible mustards:a paradigmfor hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Met Rev 1993; 12: 135-51.
34. SiimBG, Denny WA, Wilson WR. Nitro reduction as an electronic switch for bioreductive drug activation. Oncol Res 1997; 9: 357-69.
35. Helsby NA, Wheeler SJ, Pruijn FB, et al. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2, 4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862:distinct mechanisms of bioreductive activation. Chem Res Toxicol 2003; 16: 469-78.
36. Denny WA, Atwell GJ, Yang S, et al.; inventors;Auckland Uniservices Ltd, assignee. PCT/NZ 2004/529249. WO 2005/042471 A1. 2005.
37. Atwell GJ, Denny WA. Synthesisof 3H- and 2H4-labelled versions of the hypoxia-activated pre-prodrug 2-[(2- bromoethyl) -2, 4-dinitro-6-[2- (phosphonooxy) ethyl]amino]carbonyl]anilino]ethyl methanesulfonate (PR-104). J Labelled Cmpds Radiopharm 2007; 50: 7-12.
38. Guise C, Wang A, Thiel A, et al. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A:a role for NADPH:cytochrome P450 oxidoreductase under hypoxia. Biochem Pharmacol 2007; 74: 810-20.
39. Dorie MJ, Kovacs MS, Gabalski EC, et al. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine. Neoplasia 1999; 1: 461-7.
40. Douglas RS, Patterson AV, Yang S, Wilson WR, Siim BG. Induction of DNA damage and repair responses by the hypoxia-activated prodrug PR-104. EJC Supplements 2005; 11: 8973-4s.
41. Helleday T. Amplifying tumour-specific replication lesions by DNA repair inhibitors - a new era in targeted cancer therapy. Eur J Cancer 2008; 44: 921-7.
42. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434: 907-13.
43. Chan N, Koritzinsky M, Zhao H, et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 2008; 68: 605-14.
44. Patterson AV, Guise CP, Abbattista M, et al. The bioreductive prodrug PR-104 is activated under aerobic conditions by human aldo-keto reductase 1C3 (prostaglandin F synthase). EJC Supplements 2008; 6: 473.
45. Danson S, Ranson M, Denneny O, Cummings J, Ward TH. Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial. Cancer Chemother Pharmacol 2007; 60: 851-61.
46. Hartley JM, Spanswick VJ, Gander M, et al. Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Clin Cancer Res 1999; 5: 507-12.
47. Olive PL, Durand RE, Jackson SM, et al. The comet assay in clinical practice. Acta Oncol 1999; 38: 839-44.